Transrectal ultrasound-guided (TRUS) biopsy is the gold standard for evaluating suspected prostate malignancies. However, about 20% of the cancer cases are missed by TRUS (c) mainly due to missed tumors in the peri-urethral and the anterior area of the prostate. Transurethral sampling may enable sampling from these hard-to-reach areas, estimated at 15-20% of prostate biopsies (c).

Currently there is no minimally invasive access to the deep, lateral and anterior core fields of the prostate.

ProstateTransurethral access to the prostate.

(c) Norberg M. et al, Urology 1997; 50:562

Hacharuv 1A, P.O.Box 337, Rishpon 46915, Israel       Email: info@arch-medical.com       Phone: 972-3-6130335       Mobile: 972-52-4567348